This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela Power

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: May 27, 2008
Last updated: February 12, 2009
Last verified: February 2009
To prove the safety, in normal conditions, of the odontological use formulation of the product Cepacol Canela Power.

Condition Intervention Phase
Healthy Drug: Cetylpyridinium chloride Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Uni Centric Study, Phase III, for Safety Oral Mucosa Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Canela Power

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Patients will be evaluated according to the adverse reactions and the intensity of them. The volunteers will also answer a questionnaire about the physical attributes of the product. [ Time Frame: 21 days ]

Enrollment: 30
Study Start Date: January 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: I
Cetylpyridinium chloride during 21 days.
Drug: Cetylpyridinium chloride


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Integral buccal mucous (without oral pathologies);
  • Normal odontological exams;

Exclusion Criteria:

  • Lactation or gestational risk or gestation;
  • Use of Anti-inflammatory or immunosuppression drugs 15 days before the study;
  • Being in odontological treatment;
  • Pathological or mucous disease which can interfere or active gynaecological disease which may interfere wtih study results;
  • Personal history of allergic disease in the area to be treated;
  • Allergic or atopic history;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00687037

São Paulo, Brazil
Sponsors and Collaborators
Study Director: Jaderson Lima, MD Sanofi-aventis administrative office Brazil
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00687037     History of Changes
Other Study ID Numbers: CPYRY_L_03930
Study First Received: May 27, 2008
Last Updated: February 12, 2009

Keywords provided by Sanofi:
oral hygiene

Additional relevant MeSH terms:
Anti-Infective Agents, Local
Anti-Infective Agents processed this record on August 23, 2017